Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. - Wikidata - wikimedia - TriplyDB

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

http://www.wikidata.org/entity/Q43110528

about

MicroRNA-regulated viral vectors for gene therapy Non-Coding RNAs Including miRNAs and lncRNAs in Cardiovascular Biology and Disease Cardiovascular gene therapy for myocardial infarction Gene therapy targets in heart failure: the path to translation MicroRNAs in heart failure: Small molecules with major impact Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9 Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure Heart failure: advanced development in genetics and epigenetics MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis Molecular targets in heart failure gene therapy: current controversies and translational perspectives AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure Cardiac Gene Expression Knockdown Using Small Inhibitory RNA-Loaded Microbubbles and Ultrasound.Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles.RNA interference-based therapeutics for inherited long QT syndrome Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a.RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.A fabricated siRNA nanoparticle for ultra-long gene silencing in vivo.Assessment of cardiovascular fibrosis using novel fluorescent probes.Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery.Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle.Rescuing the failing heart by targeted gene transfer MicroRNAs in cardiovascular disease.SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure.Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts.Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats.Altered myocardial calcium cycling and energetics in heart failure--a rational approach for disease treatment.A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines.AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.Effectiveness of gene delivery systems for pluripotent and differentiated cells.MicroRNA delivery for regenerative medicine.The rise of cardiovascular medicine.CXCR4 gene transfer prevents pressure overload induced heart failure Critical role for stromal interaction molecule 1 in cardiac hypertrophy Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.Stroke volume-to-wall stress ratio as a load-adjusted and stiffness-adjusted indicator of ventricular systolic performance in chronic loading Potential of gene therapy as a treatment for heart failure miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway.Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

P2860

Q26745822-D927D687-1717-4F2D-A42F-48E79FF4B10C Q26999363-F9DCD34C-635B-4634-919B-E0148F23C766 Q27014770-6DC6F2A7-30B0-4A31-803E-CA3526EEF5F5 Q27022444-6F1EB18C-F186-44C3-BBA2-E80AF2F8ACEE Q27024714-14D75FFC-5DC7-4888-AE6B-5A5AFA5438DC Q27026716-2FB13018-886E-4B2E-A54F-F24991F8C777 Q27678476-3F4E253E-1612-4214-89C6-BDDE429F2649 Q27691424-7386DE0F-2297-4CD8-99F6-9EE936D77831 Q28080771-CC46260F-18D0-471C-918A-B87698DDF869 Q28115504-3807AC99-054E-4EC7-A5F5-63AA6F052CB9 Q28265749-D7B6E3F0-8AE7-4CF9-B450-3A0086127FC8 Q28568044-AD356856-4B8B-473A-BA74-725E151171BD Q30376315-49CE13FE-1AE5-4DA4-9FB7-FC9F0E81FF78 Q30454594-A9EDC3F2-D98D-445D-8DB6-5D69DBBD0417 Q33166507-D1CA59AE-76A3-46C1-A686-D59D60C92E39 Q33489603-347AA587-EFAE-423F-A675-E6437BF70DF4 Q33565464-4AFBE306-ECDB-4FF2-9786-E71FBE822EEE Q33835390-EA8F9FC3-87CE-4ADF-A7FA-AA31D4C35829 Q33886088-C44FBED8-3AB2-4120-A8C1-BBDAB2DFB730 Q33920641-E7593D13-C5AE-40F1-8571-653834B75534 Q34627089-8478F9A3-BE1E-478E-A8DE-371BD7A10B50 Q34757960-71E66ACC-6890-4444-BC59-9AA6C511FD74 Q34988737-5AF667F7-3C9D-4563-B161-EEFFE540249B Q35057816-7CE9E483-591C-4CCD-92B7-B098F621F2C0 Q35061110-1193AB95-5A00-4612-8B46-0B527B030FAB Q35072110-1F7FAA8E-2D2E-42F2-BECD-98E4DC4A820C Q35116100-B16965A8-B1D0-420E-9FCA-EEF29C8B7038 Q35132004-4E3EE324-759B-42E0-BEAB-29095E2AF360 Q35174923-B5F0EBBD-0554-40F7-9D39-F67FE9533CAF Q35238264-A6AED575-4785-434B-8029-DDC168506281 Q35665070-4B7C2ED1-E3D7-44D5-A16B-271105B726C2 Q35863950-65D77EDA-285C-4A2D-849D-0A6573974931 Q35937741-12396D18-599F-4E19-9453-53157257B4BF Q36132472-FB71289A-490E-40E8-AF0A-2383BFCDD10E Q36192690-68C14130-18C7-4B22-BFA2-A5B134299057 Q36281111-4474EC68-3E66-440B-80C1-FF90B094744F Q36320912-EB998506-9066-4397-843E-F3F3C76E07CD Q36497159-D16C26C6-C0AC-4273-814F-4CB026A31E3B Q36601680-99E1CF2F-C6A2-4A7C-BAE8-C60939DCC61C Q36824801-C5DE7FD5-EAA9-4E65-AEE1-7BAC57923583

P2860

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

http://www.wikidata.org/entity/Q43110528

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@en

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@nl

type

label

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@en

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@nl

prefLabel

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@en

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@nl

P1433

Q43110528-E0733F95-93AB-4021-BEEE-71EC2051772A

P1476

Q43110528-772D9FCF-6B70-436E-91F2-347C86AD68DF

P2093

Q43110528-0B9D9E0D-F377-4FBB-8A2C-5ECEE2AE8B84

Q43110528-1308DD84-05EA-461E-A1A2-ED5AAC2902BE

Q43110528-1635A9D9-81A0-4B4B-AA79-339A10CCCFDB

Q43110528-22F70A48-3809-4667-99EA-B663EDC4379E

Q43110528-4CCE469E-87E2-4DE8-A012-FC173A631BC6

Q43110528-4E974A03-4A85-4F5F-A575-50545DAC949D

Q43110528-53FC304E-FD01-44D9-B00C-07E42EB2BC91

Q43110528-5B3C3CF6-A0B7-4B59-A98D-D73B1E845BB3

Q43110528-6D38FE98-796F-424A-91C2-5D55167792D3

Q43110528-9930CB4D-0E4E-46FB-A92B-ADEC1B44A3BC

P2860

Q43110528-0130DE4D-E17A-4151-A65C-646F6A6D37CB

Q43110528-07B9E6D5-F085-4FA2-921C-84321FE13203

Q43110528-0BDA83C7-033E-4B0C-8D08-00A7407F7A45

Q43110528-24C8E87C-BB80-4AC3-A326-7A5658712F3B

Q43110528-3B3A65EE-86F3-424F-8423-8D7BE9CE5044

Q43110528-3C4A11E5-D71A-4449-B0FE-84B06DD27D2E

Q43110528-3F1A4A9C-A50C-40CD-9D62-911A55F4C865

Q43110528-49260524-411B-483D-AF19-E1A7F179E7FB

Q43110528-4A8D1AE2-2515-4E6B-BF1D-AD92A5325525

Q43110528-503B37BA-9AEB-4BEA-A33A-BB71BBFE95CC

P304

Q43110528-CE6C3D43-846D-4272-997A-34EBE95A28F8

P31

Q43110528-DF6B97EB-7E0F-4D11-B09C-9B5A212568A4

P356

Q43110528-FB9E3EC4-3B94-4448-824C-47AE9D156D3B

P407

Q43110528-CD9052CF-09D3-469D-ABA8-DDCD15D3B497

P433

Q43110528-76CB53F5-E481-49BE-A356-867BBDC151B4

P478

Q43110528-F9981634-D2E2-4EF3-93F8-0D33E92F6E7D

P50

Q43110528-3387296C-B573-47D2-B13E-9ACB0170FC62

Q43110528-68FE1476-A3A1-4423-ACC1-2EC206850E24

P577

Q43110528-F3421116-B3D5-4151-8C8F-D57631FB0E13

P698

Q43110528-A019DCE6-897E-4EE7-BB27-B13B32A4A0B0

P921

Q43110528-1CE58EA9-947B-4DC9-BE81-6C1764EC3634

P932

Q43110528-121E5624-6938-4D31-8FB7-6204ED6FE350

P356

CIRCULATIONAHA.108.783852

P1433

P1476

Long-term cardiac-targeted RNA ...... uces pathological hypertrophy.

@en

P2093

Carsten Tschope

http://www.w3.org/2001/XMLSchema#string

Dirk Westermann

http://www.w3.org/2001/XMLSchema#string

Djamel Lebeche

http://www.w3.org/2001/XMLSchema#string

Egbert Bisping

http://www.w3.org/2001/XMLSchema#string

Elie Chemaly

http://www.w3.org/2001/XMLSchema#string

Heinz-Peter Schultheiss

http://www.w3.org/2001/XMLSchema#string

Henry Fechner

http://www.w3.org/2001/XMLSchema#string

Hung Ly

http://www.w3.org/2001/XMLSchema#string

Isaac Sipo

http://www.w3.org/2001/XMLSchema#string

Jens Kockskämper

http://www.w3.org/2001/XMLSchema#string

P2860

A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure

Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2

The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2

Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy

Control of stress-dependent cardiac growth and gene expression by a microRNA

MicroRNA-133 controls cardiac hypertrophy

MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure

Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.

Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

P304

1241-1252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.783852

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19237664

http://www.w3.org/2001/XMLSchema#string

P921

P932

4298485

http://www.w3.org/2001/XMLSchema#string